Phase 1 Breast Cancer Trial, Recruiting NCT03863457 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Breast Cancer
Back to Breast Cancer

Phase 1 Breast Cancer Trial, Recruiting

NCT03863457
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People with known or suspected breast cancer, whether it started in the breast or has spread to other parts of the body
  • People who have at least one breast cancer lesion (area of concern) measuring 1.0 cm or larger that has already shown up on a standard scan such as a CT, MRI, mammogram, ultrasound, or PET/CT scan
  • People who are willing to be informed about the research nature of this study and sign a written consent form before any study procedures begin

Who may not be able to join:

  • People who are pregnant or breastfeeding at the time of screening (a urine pregnancy test will be carried out for women who could potentially become pregnant)
  • People who, in the opinion of the investigating or treating doctor, would not be able to tolerate the imaging procedures involved in the study
  • People who have a current medical condition, illness, or disorder that a doctor considers could affect their safety or ability to fully participate in the study (this may be identified through medical records or self-reporting)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Austin Pantel, MD, Instructor of Radiology

Phone: 215-573-6569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
5 April 2019
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Kinetics and Biodistribution of [18F]F-GLN

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov